Cite
Targeting 14-3-3 sensitizes native and mutant BCR-ABL to inhibition with U0126, rapamycin and Bcl-2 inhibitor GX15-070.
MLA
Dong, S., et al. “Targeting 14-3-3 Sensitizes Native and Mutant BCR-ABL to Inhibition with U0126, Rapamycin and Bcl-2 Inhibitor GX15-070.” Leukemia (08876924), vol. 22, no. 3, Mar. 2008, pp. 572–77. EBSCOhost, https://doi.org/10.1038/sj.leu.2405064.
APA
Dong, S., Kang, S., Lonial, S., Khoury, H. J., Viallet, J., & Chen, J. (2008). Targeting 14-3-3 sensitizes native and mutant BCR-ABL to inhibition with U0126, rapamycin and Bcl-2 inhibitor GX15-070. Leukemia (08876924), 22(3), 572–577. https://doi.org/10.1038/sj.leu.2405064
Chicago
Dong, S., S. Kang, S. Lonial, H. J. Khoury, J. Viallet, and J. Chen. 2008. “Targeting 14-3-3 Sensitizes Native and Mutant BCR-ABL to Inhibition with U0126, Rapamycin and Bcl-2 Inhibitor GX15-070.” Leukemia (08876924) 22 (3): 572–77. doi:10.1038/sj.leu.2405064.